Belrestotug
As of the edition of 20 October 2026, Belrestotug is an antibody: in active development; acts on TIGIT.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Antibody
- Registered trials
- 10, 1 stopped early
- Disease areas
- Cancer; Lungs and airways; Skin and connective tissue; Blood and lymph; Digestive system; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Belrestotug.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TIGIT | T-cell immunoreceptor with Ig and ITIM domains | Q495A1 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 1 | 2 | 1 |
| Phase 2 | 5 | 2 | 2 | 0 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 10 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| GSK | Lead sponsor of trials | 2019 to now |
| Concentra Biosciences | Lead sponsor of trials | 2020 to now |
| iTeos | Lead sponsor of trials | 2021 to now |